Corporate ProfileG1 Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapeutics for the treatment of cancer. G1’s two clinical assets, trilaciclib and G1T38, are CDK4/6 inhibitors, a validated and promising class of targets for anti-cancer therapeutics. These two product candidates have the potential to treat nearly all forms of cancer and be administered in combination with most conventional and emerging cancer therapies. In addition, G1 has exclusively in-licensed G1T48, a potential first/best-in-class oral selective estrogen receptor degrader, or SERD, which is targeted for the treatment of a particular type of breast cancer. G1 owns or holds an exclusive license for worldwide commercial rights to each of its product candidates.
Stock Information

GTHX (Common Stock)


 0.39 (2.50%)


08/18/17 4:00 p.m. ET

Stock chart for: GTHX.O.  Currently trading at $16.02 with a 52 week high of $20.60 and a 52 week low of $12.04.
Recent NewsMore >>
08/09/17G1 Therapeutics Reports Second Quarter 2017 Financial Results and Recent Operational HighlightsPrinter Friendly Version
08/08/17G1 Therapeutics to Present at Wedbush PacGrow Healthcare ConferencePrinter Friendly Version
08/03/17G1 Therapeutics Makes Key Appointments to Management TeamPrinter Friendly Version
07/27/17G1 Therapeutics to Ring Nasdaq Stock Market Closing Bell on Wednesday, August 2, 2017Printer Friendly Version
Upcoming EventsMore >>
There are currently no events scheduled.
Data provided by Nasdaq. Minimum 15 minutes delayed.